港股异动 | 绩后获多家投行唱好 翰森制药续涨5%股价再创新高
格隆汇9月3日丨翰森制药(3692.HK)继续前面连续三个交易日上涨后,于今日至现价29.05港元再度上涨5.06%,盘中最高见29.45港元续创新高,暂成交1.57亿港元,最新总市值1657.57亿港元;公司股价从上市首日至今已累计上涨逾78%。上月30日公司发布中报指,截至2019年6月30日止6个月公司收入45.99亿元人民币,同比增21.9%;母公司拥有人应占溢利12.96亿元,同比增长24.3%。里昂研报指,由于公司今年将推出数个重要产品,包括GLP-1及自主创新药氟马替尼,料2019年至2021年将可有强劲表现,分别录得盈利24.4亿元人民币、30.96亿元人民币及38.79亿元人民币。将公司目标价调升至29.55港元,维持评级“跑赢大市”。花旗集团维持公司买入评级,目标价30港元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.